| abstract |
Drug combination comprising xenon gas and at least one NMDA receptor antagonist, in liquid or solid form, to treat a disease caused by dysfunction of dopaminergic synaptic transmission resulting from wasting of the cell body, a decrease in neuritic arborization or a reduction in synaptic function, in a human patient, in which: - the NMDA receptor antagonist is chosen from memantine, nitromemantine, amantadine and ifenprodil, and - the disease caused by dysfunction of dopaminergic synaptic transmission is choose from Parkinson's disease, dyskinesias, schizophrenia, restless leg syndrome, Gilles de la Tourette syndrome, addictive behaviors, severe depression, and attention deficit disorders with or without hyperactivity. |